Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

Also called NCT05263778

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05263778
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05263778. Randomized; quadruple masking; primary purpose prevention. Start 2022-03 (anticipated); primary completion 2023-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study
Condition
Cardiovascular Diseases
Condition
NSTEMI
Condition
STEMI
Intervention (Drug)
Bempedoic Acid / Ezetimibe Oral Tablet
Intervention (Drug)
Placebo
Lead sponsor
Kaiser Permanente (class: other)
Collaborator
Esperion Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05263778
Content hash
d79aa37f51cc6103b237bb9c4dabd81a9eea11ee536de58a53072441266a4d41